相关实验视频

Updated: Jun 5, 2025

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

使用特定的脂质体输送系统通过EGCG准瘤内皮细胞可以抑制血管炎症和血栓形成

Zi Jia¹, Nako Maishi¹, Hideki Takekawa¹

¹Vascular Biology and Molecular Pathology, Hokkaido University Graduate School of Dental Medicine, Sapporo, Japan.

Cancer medicine

|December 4, 2024

概括

装入MEND纳米颗粒的epigallocatechin-3-O-gallate (EGCG) 减少了瘤内皮细胞的炎症和血栓形成. 这种有针对性的方法抑制了瘤生长,并增强了抗瘤免疫力.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
纳米医学是一种纳米医学.

背景情况:

炎症是癌症生长的关键驱动因素,促进血栓形成,是癌症死亡的主要原因.
瘤内皮细胞 (TEC) 呈现炎症表型,有助于瘤进展和血栓形成.
绿茶中的一种化合物epigallocatechin-3-O-gallate (EGCG) 已知具有抗炎性质,但其对TEC炎症和抗瘤活性的直接影响尚不清楚.

研究的目的:

通过针对TECs的炎症来研究EGCG的抗瘤作用.
评估EGCG载荷循环RGD脂质体输送系统 (EGCG-MEND) 在抑制瘤进展方面的疗效.

主要方法:

在体外研究中使用定量PCR和免疫光检测来评估EGCG对TEC基因和蛋白质表达的影响.
在体内研究中,EGCG-MEND用于瘤携带小鼠的TEC的向输送.
分析包括炎症性细胞因子表达,NF-κB信号传递,·维勒布兰德因子和免疫标记物.

主要成果:

在TEC中,EGCG通过NF-κB抑制显著降低了炎症性细胞因子表达 (TNF-α,IL-6,IL-8,IL-1β).
EGCG-MEND有效地抑制了TEC炎症和瘤内的血栓形成.
通过降低PD-L1表达和促进CD8+ T细胞透,EGCG-MEND增强了抗瘤免疫力.

结论:

通过使瘤免疫微环境正常化,EGCG-MEND显示出显著的抗瘤潜力.
使用EGCG-MEND向TEC炎症有效抑制血栓形成.
这种方法通过调节瘤微环境,为癌症治疗提供了一个新的策略.

关键词:

对于 EGCG 的情况来说,这是一项非常重要的决定.这就是ROSOS ROS.瘤内皮细胞的内皮细胞.瘤的炎症瘤的炎症瘤血栓形成瘤血栓形成

更多相关视频

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol

Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol

Published on: April 4, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...